Plain-English translation of NCT07045311 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new immunotherapy medication called JS207 combined with either another newer drug or a standard chemotherapy to treat triple-negative breast cancer that has returned or spread to other parts of the body. The trial has two groups: one receiving JS207 with a newer agent, and another receiving JS207 with a traditional chemotherapy drug. Researchers want to see if these combinations are safe and effective for patients who haven't received prior systemic treatment for their advanced cancer.
Triple-negative breast cancer is particularly aggressive and has limited treatment options because it lacks three common protein targets that other breast cancers have. This trial exists to see whether this new medication, possibly working with the immune system, can help patients live longer and control their disease better than older treatment approaches alone.
You likely qualify if…
You likely don't qualify if…
You would receive the study medication through regular clinic visits, with treatment delivered either intravenously or through other routes as determined by your assigned group. You will be monitored closely during an initial safety period, after which the study may expand to enroll more patients. Throughout the trial, you would have blood tests, imaging scans (like CT or MRI), and regular check-ins with your care team to assess how well the treatment is working and watch for side effects. The exact schedule and duration depend on how your cancer responds and how well you tolerate the medication.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China